How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
First publishedAug 5, 16:52 UTC
Last updatedAug 6, 08:33 UTC · 14m ago
1 outlet
MarketWatch
1 outlets over time — hover a bar for its window & outletslast updated
Answer
The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.
Reported by 1 outlet — MarketWatch. See all sources ↓
Read the full report at MarketWatch ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
In brief
- What's the story?
- The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.
- How widely is it covered?
- 1 outlet, average source rating 7.0/10.
- When was it last updated?
- 14m ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Sources1TypeCoverage
Related in the knowledge graph
organizationCan EuropeorganizationEli LillyorganizationGLP-organizationHow OzempicorganizationNovo NordiskorganizationThen America
Sources (1)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3